CSPC Pharmaceutical Group Limited announced that the Dapagliflozin Tablets (5mg/10mg) (the "Product") developed by the Group has obtained drug registration approval granted by the National Medical Products Administration of the People's Republic of China, and is deemed to have passed the consistency evaluation of quality and efficacy for generic drugs. Dapagliflozin is an SGLT2 inhibitor that allows excess glucose to be excreted through urine, thereby improving blood sugar control without increasing insulin secretion. The Product can be used as a monotherapy or in combination with metformin hydrochloride or insulin to improve blood sugar control on the foundation of diet and exercise.

The approval of the Product will further enrich the Group's product portfolio for metabolic diseases.